Skip to content

Drug interactions

Liposomal doxorubicin + Valganciclovir

Severity: Major

Liposomal doxorubicin and Valganciclovir: major interaction.

Last updated

For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.

Summary

Both drugs suppress bone marrow, and combined use can cause more severe neutropenia, anemia and thrombocytopenia. Valganciclovir's labeling advises caution with other myelosuppressive agents.

What this interaction means in plain words

Liposomal doxorubicin and Valganciclovir can interact in a way that may be serious. Using them together is sometimes necessary, but it needs a deliberate decision by the prescriber, a plan for monitoring, and clear advice on the warning signs to watch for.

Liposomal doxorubicin belongs to Oncology; Valganciclovir belongs to Anti Virals.

Evidence level: Moderate

Why it happens

Additive bone marrow suppression.

What to do

Monitor complete blood counts frequently, and adjust doses or use growth factors per protocol; consider an alternative antiviral if counts fall.

What to ask your pharmacist

  • Does the benefit of taking both outweigh the risk in my case?
  • Do I need any blood test, ECG or other check while on both?
  • What early warning signs should I watch for, and what should I do if they appear?

Bring a full list of your medicines, including over-the-counter products, supplements and herbal remedies, to every pharmacy visit.

Pro+ members

Unlock the full page

Create an account and start a Pro+ trial to unlock the full management advice for Liposomal doxorubicin and Valganciclovir, the additional notes, the evidence detail and the whole-prescription interaction checker.

  • Full clinical management advice
  • Additional notes
  • Evidence detail
  • Interaction checker for a whole prescription

Try Pro+ free for 14 days on the web. No card needed.

Frequently asked questions

Can I take Liposomal doxorubicin with Valganciclovir?

MediHelp rates the interaction as major. Liposomal doxorubicin and Valganciclovir can interact in a way that may be serious. Using them together is sometimes necessary, but it needs a deliberate decision by the prescriber, a plan for monitoring, and clear advice on the warning signs to watch for. Both drugs suppress bone marrow, and combined use can cause more severe neutropenia, anemia and thrombocytopenia. Valganciclovir's labeling advises caution with other myelosuppressive agents.

How serious is the interaction between Liposomal doxorubicin and Valganciclovir?

MediHelp rates it major, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Monitor complete blood counts frequently, and adjust doses or use growth factors per protocol; consider an alternative antiviral if counts fall.

What other medicines interact with Liposomal doxorubicin?

MediHelp also lists interactions of Liposomal doxorubicin with, for example, Dengue vaccine, Belatacept, Cyclosporine. The full list is on the Liposomal doxorubicin page.

Full monographs, dosing and an interaction checker in the MediHelp app

Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.

Browse A–Z · Drug interactions

Get the app Sign in